Abstract 2132
Background
Oral oncolytics imatinib (IMN), sunitinib (SNN) and pazopanib (PZN) show a high interpatient variability in pharmacokinetics. For IMN, SNN and PZN a relationship between plasma exposure and treatment outcome has been established, which supports the rationale for dose optimization of these drugs. The aim of this study was to monitor how many patients reached adequate trough levels (Cmin) after dose optimization in daily practice.
Methods
An observational study was performed in a cohort of patients treated with IMN, SNN or PZN of whom multiple drug levels were measured between August 2012 and April 2016. Patients' characteristics were collected by reviewing medical records. Drug levels were measured using LC-MS/MS and Cmin were estimated using the algorithm of Wang et al.
Results
396 trough levels were determined in 109 patients. Median sample frequency per patient was 3. During the first measurement only 38% of patients showed Cmin within the predefined target ranges: 52% of the patients showed a drug level below and 10% above target range. Dose interventions were proposed in 72 (66%) patients and implemented in 41 (38%) patients. In 35 out of 41 patients (85%) dose interventions led to an adequate Cmin. Eventually, 64% of the total cohort reached an adequate Cmin.
| Characteristics | Imatinib | (n = 70) | Sunitinib | (n = 12) | Pazopanib | (n = 27) | Total | (n = 109) |
|---|---|---|---|---|---|---|---|---|
| Drug levels (n) | 290 | 75 | 31 | 396 | ||||
| Drug levels per patient median (range) | 3 (2-13) | 2 (2-8) | 3 (2-3) | 3 (2-13) | ||||
| Cmin Measurement | First | Last | First | Last | First | Last | First | Last |
| Adequate Cmin n (%) | 29 (41) | 42 (60) | 7 (26) | 20 (74) | 5 (42) | 8 (67) | 41 (38) | 70 (64) |
| Patients with interventions n (%) | 20 (29) | 17 (63) | 4 (33) | 41 (38) | ||||
| Patients with adequate Cmin after intervention n (%) | 19 (95) | 13 (76) | 3 (75) | 35 (85) |
Conclusions
This study shows that dose optimization is an effective tool to reach adequate Cmin for patients treated with IMN, SNN and PZN. Initially, only 38% of patients had an adequate Cmin. Of the patients undergoing dose intervention 85% reached an adequate Cmin. Plasma exposure awareness might add to the improvement of efficacy and toxicity of patients treated with IMN, SNN and PZN.
Clinical trial identification
Legal entity responsible for the study
Radboudumc
Funding
Radboud University Medical Center
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
The nationwide cohort of 26,883 patients with sarcomas treated in NETSARC reference network between 2010 and 2015 in France: major impact of multidisciplinary board presentation prior to 1st treatment
Presenter: Jean-Yves Blay
Session: Sarcoma
Resources:
Abstract
Presentation
Webcast
Subgroup analysis of leiomyosarcoma (LMS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced liposarcoma (LPS) and LMS
Presenter: Jean-Yves Blay
Session: Sarcoma
Resources:
Abstract
Results of a prospective randomized phase III T-SAR trial comparing trabectedin vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS)
Presenter: Axel Le Cesne
Session: Sarcoma
Resources:
Abstract
Presentation
Webcast
Regorafenib (R) versus placebo (P) in soft tissue sarcomas (STS): analysis of genetic prognostic and predictive factors
Presenter: Thomas Brodowicz
Session: Sarcoma
Resources:
Abstract
Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): Study TH-CR-406/SARC021
Presenter: William Tap
Session: Sarcoma
Resources:
Abstract
Presentation
Webcast
PD1 and PDL1 expression, tumoral microenvironment (TME) characterization and clinical implication in localized osteosarcoma
Presenter: Emanuela Palmerini
Session: Sarcoma
Resources:
Abstract
Invited discussant abstracts 1403PD, 1404PD and 1405PD
Presenter: Silvia Stacchiotti
Session: Sarcoma
Resources:
Presentation
Webcast
Invited discussant abstracts 1401PD and 1402PD
Presenter: Xavier Garcia del Muro
Session: Sarcoma
Resources:
Presentation
Webcast
Invited discussant abstracts 1398PD, 1399PD and 1400PD
Presenter: Maud Toulmonde
Session: Sarcoma
Resources:
Presentation
Webcast
Exposure-response of olaratumab for survival outcomes and safety when combined with doxorubicin in soft tissue sarcoma (STS) patients
Presenter: Robin Jones
Session: Sarcoma
Resources:
Abstract